Log in

NASDAQ:ZLABZai Lab Stock Price, Forecast & News

$74.40
+6.04 (+8.84 %)
(As of 05/29/2020 04:00 PM ET)
Add
Compare
Today's Range
$69.13
Now: $74.40
$75.67
50-Day Range
$55.11
MA: $64.57
$73.37
52-Week Range
$25.51
Now: $74.40
$76.39
Volume2.45 million shs
Average Volume400,461 shs
Market Capitalization$4.32 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, and autoimmune and infectious disease therapies in the People's Republic of China. Its drug candidates include ZL-2306, a poly ADP ribose polymerase 1/2 inhibitor, which is in Phase III clinical trial for the treatment of ovarian, lung, and breast cancers; ZL-2401, an antibiotic that is in Phase III clinical trial to treat ABSSSI, CABP, and UTI; FPA144, a humanized monoclonal antibody, which is in Phase I/III clinical trial to treat gastric and gastroesophageal cancer; ETX2514, a novel ß-lactamase inhibitor that is in Phase II cUTI trial for the treatment of acinetobacter baumannii; and ZL-2301, which is in Phase III clinical trial to treat HCC. The company's drug candidates also comprise ZL-3101, a novel steroid-sparing topical product that is in Phase II clinical trial for the treatment of eczema and psoriasis; and ZL-2302 to treat non-small cell lung cancer. The company, through its subsidiary, Zai Lab (Shanghai) Co. Ltd., has a collaboration agreement with the NovoCure Limited to perform clinical studies, sell, and import tumor treating field products in the field of oncology. Zai Lab Limited was founded in 2013 and is headquartered in Shanghai, the People's Republic of China.
Read More
Zai Lab logo

Beat the Market (BTM) Rank

Analyst Opinion: 1.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ZLAB
CUSIPN/A
Phone86-21-6163-2588

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.98 million
Book Value$5.07 per share

Profitability

Miscellaneous

Employees309
Market Cap$4.32 billion
Next Earnings DateN/A
OptionableOptionable

Receive ZLAB News and Ratings via Email

Sign-up to receive the latest news and ratings for ZLAB and its competitors with MarketBeat's FREE daily newsletter.

Zai Lab (NASDAQ:ZLAB) Frequently Asked Questions

How has Zai Lab's stock been impacted by COVID-19 (Coronavirus)?

Zai Lab's stock was trading at $50.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ZLAB stock has increased by 48.4% and is now trading at $74.40. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Zai Lab?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zai Lab in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Zai Lab.

How were Zai Lab's earnings last quarter?

Zai Lab Ltd (NASDAQ:ZLAB) posted its quarterly earnings data on Thursday, March, 19th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by $0.05. The firm earned $4.65 million during the quarter. View Zai Lab's earnings history.

What price target have analysts set for ZLAB?

7 brokers have issued 1 year price objectives for Zai Lab's shares. Their forecasts range from $36.54 to $84.00. On average, they expect Zai Lab's stock price to reach $57.31 in the next year. This suggests that the stock has a possible downside of 23.0%. View analysts' price targets for Zai Lab.

Has Zai Lab been receiving favorable news coverage?

Media coverage about ZLAB stock has trended negative on Sunday, according to InfoTrie. InfoTrie identifies negative and positive press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zai Lab earned a news sentiment score of -2.0 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutZai Lab.

Are investors shorting Zai Lab?

Zai Lab saw a decrease in short interest in April. As of April 30th, there was short interest totaling 1,920,000 shares, a decrease of 11.9% from the April 15th total of 2,180,000 shares. Based on an average trading volume of 507,200 shares, the days-to-cover ratio is currently 3.8 days. Approximately 3.5% of the shares of the stock are sold short. View Zai Lab's Current Options Chain.

Who are some of Zai Lab's key competitors?

What other stocks do shareholders of Zai Lab own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zai Lab investors own include Crispr Therapeutics (CRSP), NVIDIA (NVDA), Inseego (INSG), InVitae (NVTA), Baozun (BZUN), Fulgent Genetics (FLGT), Intellia Therapeutics (NTLA), Beigene (BGNE), Marvell Technology Group (MRVL) and Niu Technologies (NIU).

Who are Zai Lab's key executives?

Zai Lab's management team includes the following people:
  • Dr. Ying Du, Founder, Chairman & CEO (Age 53)
  • Mr. Tao Fu, Pres, COO & Director (Age 47)
  • Mr. Ki Chul Cho, Chief Financial Officer (Age 41)
  • Dr. Ning Xu, Exec. VP and Head of Clinical & Regulatory Affairs (Age 54)
  • Dr. Qi Liu, Chief Medical Officer of Oncology (Age 54)

When did Zai Lab IPO?

(ZLAB) raised $100 million in an initial public offering on Wednesday, September 20th 2017. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. J.P. Morgan, Citigroup and Leerink Partners acted as the underwriters for the IPO.

What is Zai Lab's stock symbol?

Zai Lab trades on the NASDAQ under the ticker symbol "ZLAB."

Who are Zai Lab's major shareholders?

Zai Lab's stock is owned by a number of retail and institutional investors. Top institutional investors include Capital World Investors (10.12%), Baillie Gifford & Co. (5.36%), Wellington Management Group LLP (4.73%), BlackRock Inc. (3.56%), Federated Hermes Inc. (3.42%) and Segantii Capital Management Ltd (3.13%).

Which institutional investors are selling Zai Lab stock?

ZLAB stock was sold by a variety of institutional investors in the last quarter, including Segantii Capital Management Ltd, Orbimed Advisors LLC, Wellington Management Group LLP, AXA, Greenwoods Asset Management Ltd, Wells Fargo & Company MN, Morgan Stanley, and Invesco Ltd..

Which institutional investors are buying Zai Lab stock?

ZLAB stock was acquired by a variety of institutional investors in the last quarter, including Capital World Investors, BlackRock Inc., State Street Corp, Federated Hermes Inc., Vivo Capital LLC, Assenagon Asset Management S.A., Casdin Capital LLC, and Legal & General Group Plc.

How do I buy shares of Zai Lab?

Shares of ZLAB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Zai Lab's stock price today?

One share of ZLAB stock can currently be purchased for approximately $74.40.

How big of a company is Zai Lab?

Zai Lab has a market capitalization of $4.32 billion and generates $12.98 million in revenue each year. The company earns $-195,070,000.00 in net income (profit) each year or ($3.03) on an earnings per share basis. Zai Lab employs 309 workers across the globe.

What is Zai Lab's official website?

The official website for Zai Lab is www.zailaboratory.com.

How can I contact Zai Lab?

Zai Lab's mailing address is 4560 JINKE ROAD BLDG. 1 FOURTH FLOOR PUDONG, SHANGHAI F4, 201210. The company can be reached via phone at 86-21-6163-2588 or via email at [email protected]

This page was last updated on 5/31/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.